174 related articles for article (PubMed ID: 37327485)
1. Antibiotic Regimen Changes during Cystic Fibrosis Pediatric Pulmonary Exacerbation Treatment.
Cogen JD; Sanders DB; Slaven JE; Faino AV; Somayaji R; Gibson RL; Hoffman LR; Ren CL
Ann Am Thorac Soc; 2023 Sep; 20(9):1293-1298. PubMed ID: 37327485
[No Abstract] [Full Text] [Related]
2. Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations.
Davis CS; Faino AV; Onchiri F; Gibson RL; Merjaneh L; Ramsey BW; Rosenfeld M; Cogen JD
Ann Am Thorac Soc; 2023 Jan; 20(1):75-82. PubMed ID: 36044723
[No Abstract] [Full Text] [Related]
3. Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations.
Cogen JD; Faino AV; Onchiri F; Hoffman LR; Kronman MP; Nichols DP; Rosenfeld M; Gibson RL
Clin Infect Dis; 2021 Nov; 73(9):1589-1596. PubMed ID: 34100912
[TBL] [Abstract][Full Text] [Related]
4. Effect of Concomitant Azithromycin and Tobramycin Use on Cystic Fibrosis Pulmonary Exacerbation Treatment.
Cogen JD; Faino AV; Onchiri F; Gibson RL; Hoffman LR; Kronman MP; Rosenfeld M; Nichols DP
Ann Am Thorac Soc; 2021 Feb; 18(2):266-272. PubMed ID: 32810412
[No Abstract] [Full Text] [Related]
5. Clinical Outcomes of Antipseudomonal versus Other Antibiotics among Children with Cystic Fibrosis without
Cogen JD; Faino AV; Onchiri F; Gibson RL; Hoffman LR; Nichols DP; Rosenfeld M; Kronman MP
Ann Am Thorac Soc; 2022 Aug; 19(8):1320-1327. PubMed ID: 35289740
[No Abstract] [Full Text] [Related]
6. Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations.
Cogen JD; Faino AV; Onchiri F; Hoffman LR; Kronman MP; Nelson M; Nichols DP; Rosenfeld M; VanDevanter DR; Gibson RL
Ann Am Thorac Soc; 2020 Dec; 17(12):1590-1598. PubMed ID: 32726564
[No Abstract] [Full Text] [Related]
7. Antibiotics and outcomes of CF pulmonary exacerbations in children infected with MRSA and Pseudomonas aeruginosa.
Cogen JD; Hall M; Faino AV; Ambroggio L; Blaschke AJ; Brogan TV; Cotter JM; Gibson RL; Grijalva CG; Hersh AL; Lipsett SC; Shah SS; Shapiro DJ; Neuman MI; Gerber JS
J Cyst Fibros; 2023 Mar; 22(2):313-319. PubMed ID: 35945130
[TBL] [Abstract][Full Text] [Related]
8. The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis.
VanDevanter EJ; Heltshe SL; Skalland M; Lechtzin N; Nichols D; Goss CH
J Cyst Fibros; 2021 Nov; 20(6):932-936. PubMed ID: 33685776
[TBL] [Abstract][Full Text] [Related]
9. Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis.
Wagener JS; VanDevanter DR; Konstan MW; Pasta DJ; Millar SJ; Morgan WJ
Pediatr Pulmonol; 2020 Mar; 55(3):828-834. PubMed ID: 31746561
[TBL] [Abstract][Full Text] [Related]
10. The effect of antibiotic changes during treatment of cystic fibrosis pulmonary exacerbations.
Zikic A; Ratjen F; Shaw M; Tullis E; Waters V
J Cyst Fibros; 2022 Sep; 21(5):759-765. PubMed ID: 35650003
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of cystic fibrosis pulmonary exacerbations treated with antibiotics with activity against anaerobic bacteria.
Castner LM; Zimbric M; Cahalan S; Powell C; Caverly LJ
J Cyst Fibros; 2021 Nov; 20(6):926-931. PubMed ID: 33612403
[TBL] [Abstract][Full Text] [Related]
12. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.
Schechter MS; Regelmann WE; Sawicki GS; Rasouliyan L; VanDevanter DR; Rosenfeld M; Pasta D; Morgan W; Konstan MW
Pediatr Pulmonol; 2015 May; 50(5):431-40. PubMed ID: 25530325
[TBL] [Abstract][Full Text] [Related]
13. Evaluating FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis.
Bouzek DC; Ren CL; Thompson M; Slaven JE; Sanders DB
Pediatr Pulmonol; 2022 Jul; 57(7):1709-1716. PubMed ID: 35429154
[TBL] [Abstract][Full Text] [Related]
14. Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis.
McElvaney OJ; Heltshe SL; Odem-Davis K; West NE; Sanders DB; Fogarty B; VanDevanter DR; Flume PA; Goss CH
Ann Am Thorac Soc; 2024 May; 21(5):716-726. PubMed ID: 38096105
[No Abstract] [Full Text] [Related]
15. Predictors of pulmonary exacerbation treatment in cystic fibrosis.
Sanders DB; Ostrenga JS; Rosenfeld M; Fink AK; Schechter MS; Sawicki GS; Flume PA; Morgan WJ
J Cyst Fibros; 2020 May; 19(3):407-414. PubMed ID: 31257102
[TBL] [Abstract][Full Text] [Related]
16. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.
Heltshe SL; Goss CH; Thompson V; Sagel SD; Sanders DB; Marshall BC; Flume PA
Thorax; 2016 Mar; 71(3):223-9. PubMed ID: 25911223
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations.
Thornton CS; Caverly LJ; Kalikin LM; Carmody LA; McClellan S; LeBar W; Sanders DB; West NE; Goss CH; Flume PA; Heltshe SL; VanDevanter DR; LiPuma JJ
Ann Am Thorac Soc; 2024 Apr; 21(4):595-603. PubMed ID: 37963297
[No Abstract] [Full Text] [Related]
18. Antibiotic duration and changes in FEV
Espel JC; Palac HL; Cullina JF; Clarke AP; McColley SA; Prickett MH; Jain M
BMC Pulm Med; 2017 Nov; 17(1):160. PubMed ID: 29187171
[TBL] [Abstract][Full Text] [Related]
19. Polymicrobial infections and antibiotic treatment patterns for cystic fibrosis pulmonary exacerbations.
Faino AV; Hoffman LR; Gibson RL; Kronman MP; Nichols DP; Rosenfeld M; Cogen JD
J Cyst Fibros; 2023 Jul; 22(4):630-635. PubMed ID: 36849332
[TBL] [Abstract][Full Text] [Related]
20. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.
Sanders DB; Solomon GM; Beckett VV; West NE; Daines CL; Heltshe SL; VanDevanter DR; Spahr JE; Gibson RL; Nick JA; Marshall BC; Flume PA; Goss CH;
J Cyst Fibros; 2017 Sep; 16(5):592-599. PubMed ID: 28460885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
